# Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

> **NCT02047513** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 127 (actual)

## Conditions studied

- Resectable Pancreatic Cancer
- Ductal Adenocarcinoma of the Pancreas

## Interventions

- **DRUG:** perioperative nab-paclitaxel/gemcitabine
- **DRUG:** adjuvant nab-paclitaxel/gemcitabine

## Key facts

- **NCT ID:** NCT02047513
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2021-04
- **Final completion:** 2022-10
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047513, "Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02047513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*